November 2026

FDA requires new safety warnings for GLP-1 drugs ()
SCAI refines cardiogenic shock classifications ()
Evolocumab prevents more heart attacks than ezetimibe in head-to-head comparison ()
GE HealthCare investment in AI-powered TEE robotics part of growing automation trend ()
Startup bringing AI-powered robotics to the cath lab raises $160M from GE HealthCare, other investors ()
FDA confirms new Class I recall for heart valve delivery system due to safety risk ()
CMS finalizes more payment cuts with 2027 Medicare PFS—new policy targeting cardiologists still in place ()
For new heart patients referred to a cardiologist, telemedicine as good as in-person visits ()
CCTA matches IVUS for PCI guidance: Imaging expert Carlos Collet breaks down the data ()
Both FDA-approved renal denervation systems linked to positive real-world outcomes ()
New stroke prevention device for TAVR falls short, raising questions about the value of embolic protection ()
Combination blood pressure drug recalled after failed quality test ()
Energy drinks and stimulant supplements linked to several serious heart risks ()
Cannabis use may increase risk of CVD, stroke—even for those who only occasionally partake ()
GLP-1 drugs outperform metformin in patients with prediabetes ()
Degenerative mitral valve disease: Key takeaways from the largest study of its kind ()
TAVR linked to key benefits for select heart patients with moderate aortic stenosis ()
New heart failure data suggest some healthcare disparities are getting worse as time goes on ()
EARLY TAVR update: New data highlight economic benefits of treating asymptomatic aortic stenosis ()